Version June 2024
| Pattern of drug resistance | Suggested regimen | Duration of treatment* |
| INH, RIF | Fluoroquinolone (levofloxacin or moxifloxacin) with or without EMB | 6 to 12 months |
| INH, RIF, EMB | Fluoroquinolone (levofloxacin or moxifloxacin) with or without ETA | 6 to 12 months |
| INH, RIF, PZA | Fluoroquinolone (levofloxacin or moxifloxacin) with or without EMB | 6 to 12 months |
| INH, RIF, PZA, EMB +/– injectable | Fluoroquinolone (levofloxacin or moxifloxacin) with or without ETA | 6 to 12 months |
| INH, RIF, PZA, EMB, injectable, ETA | Fluoroquinolone (levofloxacin or moxifloxacin) with or without CS | 6 to 12 months |
| INH, RIF, PZA, EMB, fluoroquinolone (levofloxacin or moxifloxacin) | See note¶ | 6 to 12 months |
CS: cycloserine; EMB: ethambutol; ETA: ethionamide; INH: isoniazid; PAS: para-aminosalicyclic acid; PZA: pyrazinamide; RIF: rifampin.
* Longer duration (12 months) of therapy is warranted for patients with immunosuppression, children <5 years, and individuals with other substantial risk for progression to active TB disease; shorter duration (6 months) is appropriate for other individuals.
¶ When the resistance pattern limits options for treatment of latent tuberculosis to toxic combinations, clinical monitoring (symptom review every three to six months for two years with chest radiographs and/or sputum collection as clinically indicated) in the absence of treatment is reasonable. Prompt pursuit of treatment is warranted for patients with immunosuppression, children <5 years, and individuals with other substantial risk for progression to active TB disease; in such cases, possible regimens include two of the following agents: CS, PAS, and ETA.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
